AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04254848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stereognostic test
Description: Six test pieces were selected from the 20 shapes of test pieces from National Institute of Dental Research. The test pieces comprises of 6 shaped forms which include circle, plus, square, rectangular, triangle and toroid shaped. A 2mm stainless steel wire was bent forming the test piece shape following the standard dimensions (13mm length and 2mm thickness)as described by National Institute of Dental Research to serve as the test pieces mould. Using the six test piece moulds, light cured acrylic resin test samples were fabricated. The test samples were trimmed and polished to meet the standardized measurements. A total of 240 test sample (6 samples for each patient) for 20 completely edentulous patients with maxillary tori and 20 completely edentulous patients without tori were made for the study. The test pieces were attached to dental floss to prevent any accidentally aspiration during the study.
Study NCT00290550 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MK0457
Description: IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
Study NCT02064296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle acupuncture (Traditional Acupuncture)
Description: This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device (AS Super 4 digital needle stimulator).
Study NCT02064296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser acupuncture (Non-traditional Acupuncture)
Description: For non-traditional acupuncture, a laser acupuncture device (Vita Laser 650, Lhasa OMS) will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
Study NCT00821600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone IR and LAI formulation
Description: 1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
Study NCT01626690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bair-Paws Warming Device
Description: Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
Study NCT01626690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair-Hugger Warming Device
Description: Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
Study NCT04831814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Near Focus NBI
Description: Colonoscopy with near focus narrowing band imaging technology . Optical specifications include a 2 mm near field focal depth. Optical diagnosis of polyps were according to NICE and WASP, respectively.
Study NCT04831814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Focus NBI
Description: Colonoscopy with narrow band imaging technology.Optical diagnosis of polyps were according to NICE and WASP, respectively.
Study NCT03161379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
Study NCT03161379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
Study NCT03151200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer based binocular treatment
Description: Binocular amblyopia treatment involves presenting stimuli over a computer screen to the amblyopic eye those are at higher contrast compared to the stimuli that are presented to the good eye, which balances the performances of the two eyes and over time improves the amblyopic eye vision.
Study NCT03151200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.
Study NCT03151200 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.
Study NCT03161379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine
Description: Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.
Study NCT03161379 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation (SBRT)
Description: SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).
Study NCT04513301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sintilimab (200 mg q3w ×2 cycle)
Study NCT04513301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab (200 mg q3w ×2 cycle)
Study NCT04513301 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT 50-60Gy/25-30f
Study NCT03864419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC
Study NCT01490047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Infusion over 60 minutes
Study NCT01490047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx
Description: Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
Study NCT03864419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03864419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT01490047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
Study NCT04603118 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar puncture
Study NCT03838081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spielberger State Anxiety Inventory (STAI-S),
Description: STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
Study NCT03838081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dental Fear Scale (DFS)
Description: DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
Study NCT03838081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Dental Anxiety Scale (MDAS)
Description: MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
Study NCT03838081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Description: VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable
Study NCT02481934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NKAE cells infusion
Description: Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
Study NCT02481934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
Study NCT00646425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: 40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
Study NCT00646425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match basiliximab
Study NCT01902329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMA
Description: azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
Study NCT01902329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD33A
Description: Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
Study NCT02563236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parabolic flight
Study NCT01389492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: frozen meat cutlets meal
Description: 250 g of meat cutlets
Study NCT01389492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: meat meals
Description: 250 g of meat meal for 4 days
Study NCT02995239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-12420 formulation 2
Description: CJ-12420 formulation 2
Study NCT02995239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-12420 formulation 1
Description: CJ-12420 formulation 1
Study NCT03117556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Thoracoscopic Splanchnicectomy
Description: BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
Study NCT01978067 — intervention group
Intervention type: PROCEDURE
Intervention: transvaginal resection of Uterine Scar
Description: Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
Study NCT00566852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
Study NCT00566852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
Study NCT00566852 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain radiation therapy
Description: Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
Study NCT00566852 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain radiation therapy
Description: Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
Study NCT01327599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%+Timolol 0.5% ophthalmic solution
Description: Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
Study NCT04763941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CDR assessment face-to-face
Description: The assessment of the CDR is administered once by a psychologist with the patient and his caregiver.
Study NCT04346329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Treated group
Study NCT04346329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo Group
Study NCT02506634 — intervention group
Intervention type: DRUG
Intervention: Esomeprazole MUPS, 20 mg
Description: According to the guidelines, the PPI treatment duration would be 8 weeks(Esomeprazole MUPS, 20 mg bid) for patients with reflux esophagitis and 4 weeks (Esomeprazole MUPS, 20 mg bid) for patients with normal findings on endoscopy.
Study NCT04490551 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Risk-based logistic regression model
Description: The intervention will be a risk-based logistic regression model that takes multiple variables into account to calculate the risk of advanced neoplasia as an outcome.
Study NCT04490551 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FIT
Description: FIT is a stool-based test that detects human blood in faeces.
Study NCT04490551 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FIT
Description: FIT is a stool-based test that detects human blood in faeces.
Study NCT00207831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur and Uracil
Study NCT00207831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur and Uracil
Study NCT04159740 — intervention group
Intervention type: OTHER
Intervention: Tissue and blood collection
Description: Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
Study NCT02860650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Filo
Description: Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).
Study NCT02860650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo intramuscular (IM) injection at a dose of 5\*10\^8 infectious units (Inf U).
Study NCT02860650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Ad26.ZEBOV intramuscular (IM) injection at a dose of 5\*10\^10 vp.
Study NCT02860650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM injection of 0.9 percent saline.
Study NCT02860650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo intramuscular (IM) injection at a dose of 1\*10\^8 Inf U.
Study NCT03690102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-CPR
Description: Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.
Study NCT03690102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERC standardized BLS course
Description: Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
Study NCT04456062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caring Contacts
Description: Caring Contacts are brief email communications sent to the patient post-discharge. They convey messages of hope, support, promote a sense of belonging, and provide information on resources for care. They are not written uniquely for each patient but are purposefully crafted to intervene on those specific vulnerabilities that form the core of many patients' experiences with intense emotional distress and suicidal thoughts.
Study NCT02630992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate potassium
Study NCT03401502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Oral, b.i.d
Study NCT03401502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral, b.i.d
Study NCT00943930 — intervention group
Intervention type: DRUG
Intervention: THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC
Description: During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
Study NCT02934165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Safety 123
Description: Theoretically-based injury prevention videos for families
Study NCT02934165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AAP TIPP sheets
Description: American Academy of Pediatrics The Injury Prevent Program materials converted to web-based materials.
Study NCT01493973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
Study NCT01493973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03864419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT02518763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3, 100 000 IU weekly, 4 times
Study NCT02518763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25 OH vitamin D serum concentration measurements
Study NCT03243357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TF Adaptive (First Apical Binding File)
Description: Procedure: TF Adaptive System NiTi (Nickel titanium) Endo File System (SybronEndo) The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on protocol of First Apical Binding File The enlargement of the root canal will be performed with three files larger than the diameter of the previously established initial apical file.
Study NCT03864419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT03864419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03864419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT03243357 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TF Adaptive (Control)
Description: Procedure: TF Adaptive System NiTi (Nickel titanium)Endo File System The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on manufacturer's protocol The enlargement of the root canal will be performed according to the manufacturer's directions.
Study NCT00604630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin alfa
Description: 40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
Study NCT00604630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
Study NCT03864302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Motor imagery (MI) is a psychological technique for improvement of motor skills.(24) MI skill training (MIST) has been used and explored in several disciplines including Sports, Music, Education, Psychology and Medicine.(18) The literature has found positive effects on performances in professional athletes but also on rehabilitation of stroke patients.(25,26) MI is a cognitive imagery of a physical performance, e.g. a high jumper imagine a high jump, prior to performance. MI is not as effective as physical practice, but more effective compared to no training.(27) Further, MI combined with physical practice has been found to be more effective in skill performance in sports compared to physical practice alone.(18) MIST has shown promising results on surgical performances in flexible cystoscopy performed by doctors.(28)
Study NCT03081650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo Humidifier
Study NCT02023996 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-trastuzumab
Study NCT02023996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET imaging